University of Cambridge > Talks.cam > Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer > Inflammation and Cancer: Reprogramming the immune microenvironment as an anti-cancer therapeutic strategy

Inflammation and Cancer: Reprogramming the immune microenvironment as an anti-cancer therapeutic strategy

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Kate Davenport.

The concept that leukocytes are components of malignant tumors is not new; however, their functional involvement as promoting forces in tumor progression has only recently been appreciated. We are interested in understanding the molecular mechanisms that regulate leukocyte recruitment into neoplastic tissue, subsequent regulation those leukocytes exert on evolving cancer cells, and how malignant cells in turn respond to cytotoxic therapies. By studying transgenic mouse models of skin, lung, breast and pancreas cancer development, we have appreciated that adaptive leukocytes differentially regulate myeloid cell recruitment, activation, and behavior, by organ-dependent mechanisms. In turn, selective myeloid cell types provide key survival factors to malignant cells, foster angiogenic programs and invariably blunt CD8 + T cell-mediated killing of tumor cells. Treatment of transgenic mice predisposed to these various cancer types with agents that selectively block adaptive/myeloid-based programs results in slowing of primary tumor growth, improved responses to chemotherapeutic drugs, and significantly diminished presence of metastatic disease. To be presented will be recent insights into organ and tissue-specific regulation of epithelial cancer development by adaptive and innate immune cells, and new studies evaluating how attenuating protumor properties of myeloid cells can be exploited to enhance therapeutic responses to cytotoxic therapy.

LMC acknowledges generous support from the NIH / NCI, the Department of Defense Era of Hope Scholar Expansion Award, Susan G. Komen Foundation, and the Breast Cancer Research Foundation.

This talk is part of the Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.

 

© 2006-2020 Talks.cam, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity